AP
REGN icon

Anchyra Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Anchyra Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
341
-40
-10% -$27.2K 0.05% 304
2026
Q1 		$294K Sell
381
-6
-2% -$4.59K 0.09% 211
2025
Q4 		$299K Buy
+387
New +$263K 0.09% 193

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Anchyra Partners's REGN Position: Q2 2026 in Review

Anchyra Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 10% in Q2 2026, selling an estimated $27.2K and leaving 341 shares worth $213K. The position accounts for 0.05% of the portfolio, ranked #304.

Anchyra Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $299K in Q4 2025. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Anchyra Partners held 341 shares of Regeneron Pharmaceuticals worth $213K as of Q2 2026.
  • Anchyra Partners sold 40 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $27.2K.
  • Regeneron Pharmaceuticals made up 0.05% of Anchyra Partners's portfolio in Q2 2026, its #304 holding.
  • Anchyra Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Anchyra Partners's Regeneron Pharmaceuticals position peaked at $299K in Q4 2025.
  • 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.